BiOracle Gets License to Appendicitis Test

A new diagnostic test for acute appendicitis has been licensed to BiOracle, Ltd. (Congleton, UK) by DMI BioSciences, Inc. (Englewood, CO, USA).

BiOracle was granted exclusive worldwide rights to develop and commercialize DMI's patented technology. DMI will receive milestone payments and royalties on sales.

Even though appendicitis is the most common surgical emergency requiring an operation, early diagnosis relies mainly on a physical examination and signs and symptoms that may be misleading. The new point-of-care test, called Appytest, will give doctors a rapid, noninvasive assay easy to administer that has high diagnostic specificity and may reduce unnecessary hospitalizations and surgeries. No rapid diagnostic biomarker currently has high diagnostic specificity for acute appendicitis, states DMI.

"BiOracle has a very experienced team rapidly building a portfolio of preventive care products for global markets,” said Bruce Miller, president and CEO of DMI. "We are very pleased that BiOracle is commercializing a test we believe will significantly improve patient care while reducing healthcare costs.”

DMI Biosciences is a biopharmaceutical company that discovers and develops small molecule and peptide-based pharmaceuticals and biomarkers for acute and chronic inflammation. The company focuses on immunologic, vascular and central nervous system diseases, including acute coronary syndrome, multiple sclerosis, Alzheimer's disease, asthma, and cancer.




Related Links:
DMI
BiOracle